Edition:
United States

Swedish Orphan Biovitrum AB (publ) (SOBIV.ST)

SOBIV.ST on Stockholm Stock Exchange

189.10SEK
14 Dec 2018
Change (% chg)

-3.60kr (-1.87%)
Prev Close
192.70kr
Open
191.00kr
Day's High
191.00kr
Day's Low
186.20kr
Volume
1,813,887
Avg. Vol
995,674
52-wk High
299.60kr
52-wk Low
110.00kr

Latest Key Developments (Source: Significant Developments)

FDA Approves Gamifant For Primary Hemophagocytic Lymphohistiocytosis
Tuesday, 20 Nov 2018 09:40am EST 

Nov 20 (Reuters) - Swedish Orphan Biovitrum AB (publ) ::FDA APPROVES GAMIFANT® (EMAPALUMAB-LZSG), THE FIRST AND ONLY TREATMENT INDICATED FOR PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH).SWEDISH ORPHAN BIOVITRUM - GAMIFANT IS EXPECTED TO BE AVAILABLE FOR ADMINISTRATION IN TREATMENT CENTERS ACROSS U.S. IN Q1 OF 2019.  Full Article

AstraZeneca To Divest U.S. Synagis Rights To Swedish Orphan Biovitrum
Tuesday, 13 Nov 2018 02:01am EST 

Nov 13 (Reuters) - AstraZeneca PLC ::ASTRAZENECA TO DIVEST US SYNAGIS RIGHTS TO SOBI.PROPOSED DEAL FOR UPFRONT CONSIDERATION OF $1.5BN PLUS FURTHER CONTINGENT PAYMENTS.TRANSACTION GRANTS SOBI RIGHT TO PARTICIPATE IN US PROFITS AND LOSSES FOR MEDI8897.SOBI WILL COMMERCIALISE SYNAGIS IN US AND AROUND 130 ASTRAZENECA EMPLOYEES WILL TRANSFER TO SOBI AS PART OF DEAL.WILL ALSO GET UP TO $470M IN SALES-RELATED PAYMENTS FOR SYNAGIS, $175M MILESTONE AFTER BLA SUBMISSION FOR MEDI8897.  Full Article

Sobi to buy Synagis U.S. rights from Astrazeneca, pays $1.5 bln upfront
Tuesday, 13 Nov 2018 02:00am EST 

Nov 13 (Reuters) - Swedish Orphan Biovitrum ::SOBI™ TO ACQUIRE SYNAGIS® US RIGHTS FROM ASTRAZENECA - CREATES A PLATFORM FOR GLOBAL GROWTH.SAYS ENTERED INTO AGREEMENTS TO ACQUIRE PERPETUAL RIGHTS TO SYNAGIS® (PALIVIZUMAB) IN US FROM ASTRAZENECA AND TO PARTICIPATE IN 50 PER CENT OF FUTURE EARNINGS OF CANDIDATE DRUG MEDI8897 IN US.SAYS TOTAL UPFRONT CONSIDERATION CORRESPONDS TO USD 1,500 M (SEK 13.6 B.SAYS PAYMENT CONSISTING OF USD 1,000 M (SEK 9.1 B) IN CASH AND USD 500 M (SEK 4.5 B) EQUIVALENT IN NEWLY ISSUED SOBI SHARES.SAYS FOLLOWING COMPLETION OF ACQUISITION, ASTRAZENECA WILL HOLD 8.1 PER CENT OF TOTAL SHARES AND VOTES IN SOBI.SAYS SIGNIFICANT TOP LINE ADDITION WILL GIVE SOBI SUBSTANTIAL RECURRING EARNINGS TO FURTHER ADVANCE US EXPANSION AND ENABLE FUTURE STRATEGIC ACQUISITIONS OVER MID-TERM, POSITIONING COMPANY WELL FOR ITS NEXT PHASE OF GROWTH.SAYS WILL ALSO PAY USD 20 M (SEK 181 M) IN CASH, PER YEAR, FOR THREE YEARS 2019-2021 AS CONSIDERATION FOR MEDI8897.SAYS MAY PAY UP TO USD 470 M (SEK 4.3 B) FOR SYNAGIS SALES-RELATED MILESTONES FROM 2026 ONWARDS, PLUS, USD 175 M (SEK 1.6 B) FOLLOWING SUBMISSION OF BIOLOGICS LICENSE APPLICATION (BLA) TO US FOOD AND DRUG ADMINISTRATION (FDA) FOR MEDI8897.SAYS AGREEMENT ALSO INCLUDES POTENTIAL NET PAYMENTS OF APPROXIMATELY USD 110 M (SEK 1.0 B) ON ACHIEVEMENT OF OTHER MEDI8897 PROFIT AND DEVELOPMENT-RELATED MILESTONES.SAYS COMPLETION OF ACQUISITION IS SUBJECT TO CERTAIN CUSTOMARY CONDITIONS AND REGULATORY APPROVALS.  Full Article

Pharma Mar Signs Deal With Impilo Pharma For Yondelis
Friday, 27 Jul 2018 05:47am EDT 

July 27 (Reuters) - Pharma Mar Sa ::SIGNS DEAL WITH IMPILO PHARMA FOR EXCLUSIVE PROMOTION AND DISTRIBUTION OF YONDELIS IN NORDICS AND EASTERN EUROPE.SAYS WILL RECEIVE AN UP-FRONT PAYMENT OF 2 MILLION EUROS.AGREEMENT WILL REPLACE CURRENT AGREEMENT BETWEEN PHARMA MAR AND SWEDISH ORPHAN BIOVITRUM INTERNATIONAL.  Full Article

Sobi Q2 core profit beats expectations, raises forecast
Wednesday, 18 Jul 2018 02:00am EDT 

July 18 (Reuters) - Swedish Orphan Biovitrum AB ::Q2 TOTAL REVENUES OF SEK 2,289 M (1,639) FOR Q2.Q2 EBITA INCREASED BY 94 PER CENT TO SEK 951 MLN (492) FOR Q2.SAYS SOBI EXPECTS TOTAL REVENUES FOR FULL-YEAR TO BE IN RANGE OF SEK 8,600-8,800 M (7,900-8,100)..SAYS GROSS MARGIN IS EXPECTED TO BE AT LEAST 70 PER CENT (UNCHANGED).SAYS SOBI EXPECTS EBITA FOR FULL-YEAR TO BE IN RANGE OF SEK 3,400-3,600 M (2,800-3,000).REUTERS POLL: SOBI Q2 EBITA WAS SEEN AT 783 MILLION SEK, REVENUES AT 2,111 MILLION.  Full Article

Sobi raises outlook as Q3 core profit beats expectations
Wednesday, 25 Oct 2017 02:00am EDT 

Oct 25 (Reuters) - Swedish Orphan Biovitrum Ab (Publ) :Swedish orphan biovitrum q3 ‍ebita was sek 536 m (282)​.Swedish orphan biovitrum says ‍sobi now expects total revenues for full year to be in range of sek 6,300 to 6,400 m (6,100-6,200)​.Swedish orphan biovitrum says ‍gross margin is expected to be around 70 per cent​.Swedish orphan biovitrum q3 ‍total revenue was sek 1,601 m​.Swedish orphan biovitrum says ‍now expects ebita for full year to be in range of sek 1,900 to 2,000 m (1,700-1,800)​.Swedish orphan biovitrum says ‍growth strategy has been designed to capitalise on substantial potential in haemophilia​.Swedish orphan biovitrum says ‍based on this solid platform we will further balance business with a broader specialty care portfolio to ensure a sustainable company in both short and long-term​.Swedish orphan biovitrum says to decentralise decision making towards the country organisations, resource allocation to support this strategic initiative will be reflected accordingly‍​.Swedish orphan biovitrum says we are rebalancing our geographical footprint in our existing markets by, among other things, scaling and developing our north american franchise‍​.Swedish orphan biovitrum says the strengthening of our late stage research and development pipeline is another key area of focus going forward‍​.Reuters poll: sobi q3 ebita was seen at 509 million sek, revenues at 1,636 million.  Full Article

BRIEF-FDA Approves Gamifant For Primary Hemophagocytic Lymphohistiocytosis

* FDA APPROVES GAMIFANT® (EMAPALUMAB-LZSG), THE FIRST AND ONLY TREATMENT INDICATED FOR PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH)